Alto Neuroscience, Inc. Capital Expenditures Incurred but Not yet Paid
Alto Neuroscience, Inc. (ANRO) reported Capital Expenditures Incurred but Not yet Paid of $941.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-12
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $0.00.
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $941.00K.
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $3.73M.
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $0.00.
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $3.73M.
- Alto Neuroscience, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $941.00K 10-Q · filed 2026-08-12 | $4.67M derived: sum of 3 quarters · filed 2026-08-12 | $4.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $941.00K 10-Q · filed 2026-05-13 | $4.67M derived: sum of 2 quarters · filed 2026-05-13 | $4.67M derived: sum of 3 quarters · filed 2026-05-13 | $4.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.73M derived: sum of 2 quarters · filed 2026-03-16 | $3.73M derived: sum of 3 quarters · filed 2026-08-12 | $3.73M 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2025-11-12 | -$32.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | -$32.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | -$32.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-12 | |||
| 2024-03-31 | $321.00K 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |